Evidence map›Paper›PMID 32845887›Full record

ArticlePloS one2020

Association of worsening of nonalcoholic fatty liver disease with cardiometabolic function and intestinal bacterial overgrowth: A cross-sectional study.

Marília Marques Pereira Lira, José Eymard Moraes de Medeiros Filho, Vinícius José Baccin Martins, Gitana da Silva, Francisco Antônio de Oliveira Junior, Éder Jackson Bezerra de Almeida Filho, Alexandre Sérgio Silva, João Henrique da Costa-Silva, José Luiz de Brito Alves

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Marília Marques Pereira LiraDepartment of Nutrition, Health Sciences Center, Federal University of Paraiba, João Pessoa, Brazil.ORCID 0000-0003-3910-3317
José Eymard Moraes de Medeiros FilhoDepartment of Internal Medicine, Medical Sciences Center, Federal University of Paraiba, João Pessoa, Brazil.
Vinícius José Baccin MartinsDepartment of Physiology and Pathology, Health Sciences Center, Federal University of Paraiba, João Pessoa, Brazil.ORCID 0000-0002-0327-538X
Gitana da SilvaLauro Wanderley Hospital, Federal University of Paraiba, João Pessoa, Brazil.
Francisco Antônio de Oliveira JuniorDepartment of Physiology and Pathology, Health Sciences Center, Federal University of Paraiba, João Pessoa, Brazil.ORCID 0000-0003-3121-1890
Éder Jackson Bezerra de Almeida FilhoDepartment of Physical Education, Health Sciences Center, Federal University of Paraiba, João Pessoa, Brazil.
Alexandre Sérgio SilvaDepartment of Physical Education, Health Sciences Center, Federal University of Paraiba, João Pessoa, Brazil.
João Henrique da Costa-SilvaDepartment of Physical Education and Sport Sciences, Federal University of Pernambuco, Vitória de Santo Antão, PE, Brazil.
José Luiz de Brito AlvesDepartment of Nutrition, Health Sciences Center, Federal University of Paraiba, João Pessoa, Brazil.ORCID 0000-0003-4696-3809
Universidade Federal da Paraíba · BRUniversidade Federal de Pernambuco · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsNon-alcoholic fatty liver disease (NAFLD) has been associated with small bowel bacterial overgrowth (SIBO) and cardiometabolic dysfunction. This cross-sectional study aimed to evaluate the cardio-metabolic parameters and SIBO in patients with different degrees of hepatic fibrosis estimated by NAFLD fibrosis score (NFS).

methodsSubjects (n = 78) were allocated to three groups: Healthy control (n = 30), NAFLD with low risk of advanced fibrosis (NAFLD-LRAF, n = 17) and NAFLD with a high risk of advanced fibrosis (NAFLD-HRAF, n = 31). Anthropometrics, blood pressure, electrocardiogram and heart rate variability (HRV) were evaluated. Only the NAFLD-LRAF and NAFLD-HRAF groups were submitted to blood biochemical analysis and glucose hydrogen breath tests.

resultsThe NAFLD-HRAF group had higher age and body mass index when compared to the control and NAFLD-LRAF groups. The prevalence of SIBO in the NAFLD group was 8.33%. The low frequency/high-frequency ratio (LF/HF ratio) was augmented in NAFLD-LRAF (p < 0.05) when compared with control group. NAFLD-HRAF group had a wide QRS complex (p < 0.05) and reduced LF/HF ratio (p < 0.05) compared to the control and NAFLD-LRAF groups. Serum levels of albumin and platelets were more reduced in the NAFLD-HRAF subjects (p < 0.05) than in the NAFLD-LRAF.

conclusionsNAFLD impairs cardiac autonomic function. Greater impairment was found in subjects with a worse degree of hepatic fibrosis estimated by NFS. Hypoalbuminemia and thrombocytopenia were higher in subjects with a worse degree of hepatic fibrosis, whereas prevalence of SIBO positive was similar between the groups.

Indexed as

Disease ProgressionAdultBacteriaCase-Control StudiesCross-Sectional StudiesElectrocardiographyFemaleFibrosisHeart RateHumansIntestinesMaleMiddle AgedMyocardiumNon-alcoholic Fatty Liver DiseaseRisk

Identifiers

PMID32845887
PMCPMC7449384
OpenAlexW3080631479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.